A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children’s Oncology Group study
Publication
, Journal Article
Kreissman, SG; Villablanca, JG; Seeger, RC; Grupp, SA; London, WB; Maris, JM; Park, JR; Cohn, SL; Matthay, KK; Reynolds, CP
Published in: Journal of Clinical Oncology
May 20, 2008
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15_suppl
Start / End Page
10011 / 10011
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kreissman, S. G., Villablanca, J. G., Seeger, R. C., Grupp, S. A., London, W. B., Maris, J. M., … Reynolds, C. P. (2008). A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children’s Oncology Group study. Journal of Clinical Oncology, 26(15_suppl), 10011–10011. https://doi.org/10.1200/jco.2008.26.15_suppl.10011
Kreissman, S. G., J. G. Villablanca, R. C. Seeger, S. A. Grupp, W. B. London, J. M. Maris, J. R. Park, S. L. Cohn, K. K. Matthay, and C. P. Reynolds. “A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children’s Oncology Group study.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 10011–10011. https://doi.org/10.1200/jco.2008.26.15_suppl.10011.
Kreissman SG, Villablanca JG, Seeger RC, Grupp SA, London WB, Maris JM, et al. A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children’s Oncology Group study. Journal of Clinical Oncology. 2008 May 20;26(15_suppl):10011–10011.
Kreissman, S. G., et al. “A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children’s Oncology Group study.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 10011–10011. Crossref, doi:10.1200/jco.2008.26.15_suppl.10011.
Kreissman SG, Villablanca JG, Seeger RC, Grupp SA, London WB, Maris JM, Park JR, Cohn SL, Matthay KK, Reynolds CP. A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children’s Oncology Group study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):10011–10011.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15_suppl
Start / End Page
10011 / 10011
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences